Richardson v. L'Oreal USA, Inc. , 951 F. Supp. 2d 104 ( 2013 )


Menu:
  •                               UNITED STATES DISTRICT COURT
    FOR THE DISTRICT OF COLUMBIA
    ALEXIS RICHARDSON, et al.,
    individually and on behalf of all others
    similarly situated,
    Plaintiffs,                                      Civil Action No. 13-508 (JDB)
    v.
    L’ORÉAL USA, INC.,
    Defendant.
    MEMORANDUM OPINION
    In this case, plaintiffs allege that defendant L’Oréal USA, Inc., falsely and deceptively
    labeled several products as available exclusively in salons. The parties have moved for
    preliminary approval of a proposed settlement and preliminary certification of the settlement
    class. After careful consideration of the supporting memorandum and the accompanying
    exhibits, the Court will grant the motion for preliminary approval of the settlement and
    preliminary certification of the settlement class.
    BACKGROUND
    Plaintiffs filed this action on April 15, 2013, alleging that defendant L’Oréal falsely and
    deceptively labeled its Matrix Biolage, Redken, Kérastase, and Pureology products as available
    only in salons when the products can be purchased in non-salon retail establishments including
    Target, Kmart, and Walgreens. See Compl. [Docket Entry 1] ¶¶ 1, 29 (Apr. 15, 2013). Plaintiffs
    allege that the salon-only label implies a superior quality product and builds a cachet that allows
    L’Oréal to demand a premium price. See id. ¶ 27. Plaintiffs acknowledge that L’Oréal has
    developed a campaign to fight the diversion—i.e., the sale of salon-only products through stores
    1
    that do not have a salon—for each of the product lines at issue in this litigation. See id. ¶¶ 30-37.
    But plaintiffs allege that, despite L’Oréal’s efforts, the products are available in non-salon
    establishments, and argue that L’Oréal’s labeling and advertising for these products is hence
    deceptive and misleading. See id. ¶ 46.
    Soon after filing this case, the parties filed a motion for preliminary approval of their
    proposed settlement. The terms of the proposed Settlement Agreement include the following:
       Settlement Class: A Settlement Class of “all consumers nationwide who
    purchased the L’Oréal Products for personal, family or household use on or after
    August 30, 2008.” The Class excludes a few specific categories of consumers,
    such as those who purchased the products for resale, stylists, salon owners, those
    employed by L’Oréal or by plaintiffs’ counsel, and Court staff connected to this
    action. See Proposed Settlement Agreement [Docket Entry 9-2] ¶ 1.13 (May 15,
    2013).
       Relief: The settlement provides for injunctive relief only. L’Oréal will remove the
    contested claims from U.S. advertising and from labeling on products for U.S.
    distribution, except for certain products also sold or distributed in European
    countries using the same packaging; L’Oréal will not use the claims for at least
    five years, and, after five years, it may resume using the claims in markets with a
    60% reduction from 2012 levels of non-salon sales; L’Oréal will cease
    manufacturing labels for U.S. products that carry the claims and will remove the
    claims from websites and promotion materials shortly after the agreement
    becomes effective, but it will not destroy products or product packaging in its
    inventory. Id. ¶ 2.4.
    2
       Treatment of Class Representatives: Class representatives will petition for an
    incentive award of no more than $1000 each. Id. ¶ 2.5.
       Attorneys’ Fees: L’Oréal will not oppose an application by plaintiffs’ counsel for
    attorneys’ fees, costs, and expenses up to $950,000. The Agreement provides that
    the award of fees is separate from settlement; if the Court approves only a lower
    fee award, the remainder of the settlement will remain binding. Id. ¶ 2.6.
       Notice: Because L’Oréal lacks records to identify the vast majority of consumers
    who purchased the relevant products and where such purchases were made, the
    parties will publish a short-form notice in the legal notices section of USA Today
    for one week in the Monday-Thursday edition. The notice will refer proposed
    class members to a comprehensive website that will contain additional
    information, including a copy of the proposed agreement. Objections by class
    members will have to be filed no fewer than 30 days prior to the Fairness Hearing.
    Id. ¶¶ 3.2, 3.5.
       Release: Upon final approval of the settlement, class members will release
    L’Oréal from liability for the alleged conduct or any related conduct, except as to
    individual (as opposed to class-wide) claims for monetary relief. Id. ¶ 4.6.
    ANALYSIS
    I.       Preliminary Approval of Proposed Settlement
    “Preliminary approval of a proposed settlement to a class action lies within the sound
    discretion of the court.” See In re Vitamins Antitrust Litig., No. 99-197, 
    1999 WL 1335318
    , at
    *5 (D.D.C. Nov. 23, 1999). The Court will generally grant preliminary approval of a class action
    settlement if it appears to fall “within the range of possible approval” and “does not disclose
    3
    grounds to doubt its fairness or other obvious deficiencies, such as unduly preferential treatment
    of class representatives or of segments of the class, or excessive compensation for attorneys.”
    Trombley v. Nat’l City Bank, 
    759 F. Supp. 2d 20
    , 23 (D.D.C. 2011) (internal quotation marks
    omitted); see also Newberg on Class Actions, § 11:25 (4th ed. 2013). The Court will consider (1)
    whether the proposed settlement appears to be “the product of serious, informed, non-collusive
    negotiations,” (2) whether it falls within the range of possible judicial approval, and (3) whether
    it has any obvious deficiencies, such as granting unduly preferential treatment. See In re
    Vitamins Antitrust Litig., No. 99-197, 
    1999 WL 1335318
    , at *5 (internal quotation marks
    omitted).
    The Court will first consider the process that resulted in the proposed agreement. “When
    a settlement is negotiated prior to class certification . . . it is subject to a higher degree of scrutiny
    in assessing its fairness.” D’Amato v. Deutsche Bank, 
    236 F.3d 78
    , 85 (2d Cir. 2001); see also In
    re Vitamins Antitrust Litig., 
    305 F. Supp. 2d 100
    , 105 (D.D.C.2004) (observing that settlement
    must not “come too early to be suspicious”). These considerations pose no obstacle here.
    Although the action’s history in this Court has been short, the litigation history between these
    parties as to these claims is substantial, and has allowed time for meaningful arm’s-length
    negotiations. The plaintiffs originally filed some of these claims in the Northern District of
    California. See Ligon v. L’Oréal USA, Inc., No. 12-4585 (N.D. Cal. Aug. 30, 2012). They then
    engaged in negotiations. See Halunen Decl. [Docket Entry 9-3] ¶ 4 (May 15, 2013). In the course
    of those negotiations, L’Oréal provided plaintiffs with extensive documents and information
    relating to its anti-diversion and labeling practices. 
    Id.
     Plaintiffs’ counsel examined prices
    charged and conducted legal and factual research to determine the most reasonable and attainable
    resolution. Id. ¶¶ 5-6. The parties attended an in-person mediation session before the Honorable
    4
    Ronald Sabraw and finalized the agreement’s details in telephonic mediation sessions over the
    ensuing weeks. Id. ¶ 7. They worked out attorneys’ fees and costs through a second in-person
    mediation session and additional settlement discussions. Id. ¶ 8. Pursuant to the tentative
    agreement, plaintiffs voluntarily dismissed the California action and filed their claims in this
    Court. See Settlement Agreement ¶¶ D-E. Based on this process, the Court finds that informal
    discovery gave counsel “sufficient information . . . to reasonably assess the risks of litigation vis-
    à-vis the probability of success and range of recovery,” Trombley, 759 F. Supp. 2d at 26 (internal
    quotation marks omitted), and that the proposed Settlement Agreement is “the product of serious,
    informed, non-collusive negotiations,” In re Vitamins Antitrust Litig., No. 99-197, 
    1999 WL 1335318
    , at *5 (internal quotation marks omitted).
    Turning, then, to the substance of the agreement, the Court asks whether it falls within
    the range of possible approval. Both parties recognize substantial risks of proceeding with the
    litigation, and substantial costs, in terms of both time and money, in doing so. Although the
    proposed settlement provides only for equitable relief, plaintiffs assert that this limit reflects the
    risk they face in attempting to certify a damages class. First, assessing the value of the salon-only
    claims to consumers would be difficult, and L’Oréal has never attempted to do so. Second,
    assessing damages on a class-wide basis would be even more difficult—the information provided
    during the negotiation process revealed substantial price variations among retailers and in
    different regions, and indicated that non-salon retailers often sell the products at a lower price
    than do salon retailers, making damages to those purchasing the product in non-salon
    establishments difficult to analyze. Due to the valuation difficulty, plaintiffs’ counsel represents
    that proving monetary damages for a class of consumers would be challenging. “Opinion of . . .
    experienced and informed counsel should be afforded substantial consideration by a court in
    5
    evaluating the reasonableness of a proposed settlement.” In re Lorazepam & Clorazepate
    Antitrust Litig., No. 99-0790, 
    2003 WL 22037741
    , *6 (D.D.C. June 16, 2003). The Court affords
    counsel’s assessment such deference here. And class members will retain their right to seek
    damages in individual actions, dispelling many concerns about foregone payments. In these
    circumstances, an equitable-relief-only settlement may be approved. The equitable relief that is
    contemplated, moreover, directly addresses plaintiffs’ allegations by resolving the allegedly false
    and deceptive behavior. The Court hence finds that the proposed settlement lies within the range
    of possible approval.
    Finally, the agreement has no obvious deficiencies. The nominal incentive payments of
    up to $1000 for the lead plaintiffs appear reasonable. See Radosti v. Envision EMI, LLC, 
    760 F. Supp. 2d 73
    , 79 (D.D.C. 2011) (“[I]ncentive awards are not uncommon in common-fund-type
    class actions and are used to compensate plaintiffs for the services they provided and the risks
    they incurred during the course of the class action litigation.”). The proposed maximum award of
    $950,000, for attorneys’ fees, costs, and expenses, while high, is not outside the range of possible
    approval given the parties’ agreement as to the amount. Nor is approval of the full fee figure a
    condition of the settlement—pursuant to the agreement’s terms, if the Court finds a reduced fee
    award appropriate, the remainder of the settlement will continue to bind the parties and class
    members. See Settlement Agreement ¶ 2.6(c). The Settlement Agreement hence passes muster
    under preliminary review.
    CONCLUSION
    For the reasons stated above, the Court will preliminarily approve the proposed
    settlement and class certification. The Court will also set a Fairness Hearing for October 11,
    2013, at 9:00 a.m. A separate Order will be issued on this date.
    6
    /s/
    JOHN D. BATES
    United States District Judge
    Dated: June 27, 2013
    7
    

Document Info

Docket Number: Civil Action No. 2013-0508

Citation Numbers: 951 F. Supp. 2d 104

Judges: Judge John D. Bates

Filed Date: 6/27/2013

Precedential Status: Precedential

Modified Date: 8/31/2023